Supercharge Your Innovation With Domain-Expert AI Agents!

Anti-IL-11R antibody and application thereof

A technology of antibody and variable region, applied in the direction of antibody, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, anti-animal/human immunoglobulin, etc., can solve the problem of unsatisfactory curative effect and achieve Good clinical application prospects, inhibition of fibrosis, and good thermal stability

Active Publication Date: 2021-12-03
SUNSHINE LAKE PHARM CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, there are very few drugs for the treatment of fibrosis on the market. For example, there are only two drugs for pulmonary fibrosis currently on the market, pirfenidone and nintedanib, and the efficacy of these two drugs is not satisfactory

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-IL-11R antibody and application thereof
  • Anti-IL-11R antibody and application thereof
  • Anti-IL-11R antibody and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0116] The preparation of embodiment 1 antigen

[0117] Design a fusion protein of signal peptide, human IL-11RA protein extracellular domain and human IgG1 Fc from the amino terminal to the carboxyl terminal, wherein the amino acid sequence of the signal peptide is SEQ ID NO: 27 1-21 , the amino acid sequence of the extracellular domain of human IL-11RA protein is 22-367 of SEQ ID NO:27. The nucleic acid sequence encoding the fusion protein was constructed on the pcDNA3.4 vector to obtain the expression vector pcDNA3.4-IL11R-Fc; using the transient method (ExpiFectamineCHO Transfection Kit, Thermo Fisher; product number: A29129), the pcDNA3.4-IL11R-Fc was transformed into IL11R-Fc was transfected into mammalian cell CHO and expressed for 14 days; the cell supernatant was harvested after the expression was completed, and purified using Protein A purification column (GE Healthcare, Cat: 17040201); after ultrafiltration, the recombinant protein used for immunizing animals was ob...

Embodiment 2

[0118] Embodiment 2 animal immunization

[0119] Female Balb / c mice (purchased from Hunan Slack Jingda Experimental Animal Co., Ltd.) were taken, and the recombinant protein antigen IL-11R-Fc prepared in Example 1 was fully emulsified with an immune adjuvant to immunize the animals. The immunization process is as follows: Table 4 shows.

[0120] Table 4 Arrangement of immunized animals

[0121]

[0122]

Embodiment 3

[0124] Example 3 Fusion and screening of antibody-secreting cells

[0125] The mouse splenocytes isolated in Example 2 were fused with the immortalized mouse myeloma cells SP2 / 0, and the obtained fused cells were plated in a 96-well plate for pressurized selection and cultured statically for about 14 days. Wherein the medium in the 96-well plate is configured according to the following formula: 1 × HAT medium supplement (Gibco, H0137-10VL), 10% Hybridoma Feeder addition factor (Boaolong, CM-2001), 1 × L-Glutamine 200mM ( RPMI 1640 medium of Gibco, 25030-081), 1 x Penicillin-Streptomycin (Gibco, 15140-122) and 10% FBS (Gibco, 10091-148). After the fused cells grew into clonal clusters, the cell supernatant was taken for antigen-binding ELISA screening. Through ILISA screening, the fused cell mass that can bind to IL-11R-his was transferred to a 24-well plate and cultured for 3 days, and then the supernatant was taken for ELISA affinity detection again. The cells that were bou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an anti-IL-11R antibody and an application thereof. The antibody has relatively high neutralizing activity on IL-11R. Under the action of the anti-IL-11R antibody, fibrosis of lung fibroblasts HFL-1 can be effectively inhibited, and the anti-IL-11R antibody has good thermal stability and has good clinical application prospects in the aspect of treatment of fibrosis-related diseases.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to an anti-IL-11R antibody and its application. Background technique [0002] Interleukin 11 (IL-11) is a cytokine secreted by bone marrow stromal cells, and the human IL-11 gene is located in the q13.3-q13.4 region of chromosome 19. IL-11 is a member of the IL-6 cytokine family, which also includes IL-27, IL-31, leukemia inhibitory factor (LIF), oncostatin M (OSM), and ciliary neurotrophic factor (CNTF). IL-6 family cytokines induce signal transduction via the common signaling receptor beta subunit gp130 and the specific receptor alpha subunit. As for IL-11, binding of this cytokine to its specific receptor IL-11Rα induces gp130 homodimerization and acts on effector cells primarily through activation of the JAK1 / STAT3 (protein tyrosine kinase pathway) pathway to promote hematopoietic progenitor cells Differentiate and mature, maintain the homeostasis of epithelial cells, and stimulat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28C12N15/85C12N5/10A61K39/395A61P1/16A61P11/00A61P13/12A61P13/10A61P9/00A61P9/14A61P27/02A61P17/00A61P1/18A61P1/00A61P25/00A61P15/08A61P15/14A61P21/00
CPCC07K16/2866C12N15/85A61P1/16A61P11/00A61P13/12A61P13/10A61P9/00A61P9/14A61P27/02A61P17/00A61P1/18A61P1/00A61P25/00A61P15/08A61P15/14A61P21/00C07K2317/565C07K2317/56A61K2039/505
Inventor 周加滔陈苍沙万云凤曹生田徐愉林李文佳
Owner SUNSHINE LAKE PHARM CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com